Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HRS 7535

Next Previous
X
Search
Drug Profile

HRS 7535

Alternative Names: HRS-7535; KAI-7535

Latest Information Update: 17 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shandong Suncadia Medicine
  • Developer Jiangsu Hengrui Medicine Co.; Shandong Suncadia Medicine
  • Class Antihyperglycaemics; Obesity therapies; Small molecules
  • Mechanism of Action Glucagon-like peptide-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 01 Dec 2024 Shandong Suncadia Medicine plans a phase I trial for Diabetes mellitus (In volunteers, In adults) in China (PO) (NCT06727838)
  • 12 Nov 2024 Shandong Suncadia Medicine plans a phase II trial for Obesity in China (PO, Tablet) in November 2024 (NCT06671821)
  • 04 Nov 2024 Shandong Suncadia Medicine plans a phase III OUTSTAND-1 trial for Type 2 diabetes mellitus in China (PO, Tablet) in November 2024 (NCT06672172)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top